Editor's Corner: Who are the most influential people in biopharma today? We're asking you


Once again, we at FiercePharma and FierceBiotech are putting together a list of the year’s most influential people in biopharma. And we want your help.

Using our online form, we’re asking you, our readers, to make nominations and help us decide who should be part of that group.

What do we mean by “influential,” exactly? We’re looking for people who are impacting their own companies and organizations, sure, but those also who are making a mark on the wider industry. When all is said and done, our aim is to have a list of trailblazers and trendsetters in 2017.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Of course, there’s no one particular way to do it. In the past, we’ve featured everyone from activist investors to science whizzes to cost watchdogs, from dealmaking geniuses to politicians to CEOs. Need a refresher? Here are our editions of the report from 2016, 2015, 2014, and 2013.

A few other guidelines as you make your recommendations: Feel free to submit as many nominees as you'd like, though you'll have to fill out a separate form for each. We’ll include someone who’s made the cut before, provided you can make the case that there’s a new, timely reason they should be featured this year in particular. And we’ll be closing the polls one week from today, on Tuesday, Feb. 14.

With that, nominate away. We look forward to reading your submissions. — Carly Helfand (email | Twitter)

Access the nomination form >>


Suggested Articles

Troubled Allergan is taking steps to appease investors, including bringing in a big-name biotech exec for guidance. But not everyone is impressed.

Bayer and J&J agreed to pay $775 million to wrap up about 25,000 lawsuits claiming their Xarelto anticoagulant caused severe bleeding.

The Monsanto acquisition "was and is a good idea," says Bayer chief executive, even as the company lost phase 1 of the first bellwether Roundup trial.